Cutting-edge therapeutic advances progress for diverse diseases. Iambic Therapeutics disclosed potent preclinical activity of IAM-1363, an irreversible HER2 inhibitor, in non-small cell lung cancer models. Dewpoint Therapeutics secured Series D funding to advance its condensate modulator DPTX-3186 toward clinical trials in gastric cancer. Avidity Biosciences showed promising phase I/II data reversing Duchenne muscular dystrophy progression, and Maze Therapeutics’ positive Phase I results for phenylketonuria and chronic kidney disease support transitioning to Phase II. These developments mark significant strides in precision medicine and rare disease treatment landscapes.